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Nowadays radiotherapy and adjuvant endocrine therapy represent a standard treatment option in management of breast cancer. Melatonin exerts oncostatic actions on human breast cancer cells. Therefore, the purpose of this study was to 
investigate the effects of a combination of radiotherapy and melatonin on human breast cancer cells. Radiation inhibited MCF-7 
cell proliferation in a dose-dependent manner, and pretreatment with melatonin one week before radiation led to a significantly 
decrease of cell proliferation compared with radiation alone. Melatonin pretreatment also decrease G2-M phase arrest compared 
with radiation alone, with a higher percentage of cells in G0-G1 phase and a lower percentage of cells in S phase. Regarding 
double-strand DNA break repair proteins, melatonin led to a significantly greater decrease in RAD-51 and DNA-PKcs mRNA 
gene expression compared with radiation alone. Melatonin pretreatment also upregulated the tumor suppressor p53. We have also 
demonstrated that melatonin pretreatment induced a greater decrease in aromatase and sulfatase, two main enzymes involved in 
the tumoral synthesis of estrogens, compared with radiation alone. Therefore, melatonin reduces active estrogens levels at tumoral 
cell. This is an important finding since anti-estrogens and anti-aromatase drugs have potential application with radiotherapy. Our 
findings suggest that melatonin may act as a radiaosensitizer in breast cancer cells by inhibiting tumor alestrogen production, 
decreasing cell proliferation, inducing cell cycle arrest and down-regulating proteins involved in double-strand DNA break repair 
through its regulatory action on p53. Thus, these results may have high translational potential for the adjuvant therapy in breast 
cancer patients.
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